Skip to main content
Figure 1 | Breast Cancer Research

Figure 1

From: Peroxiredoxin-1 protects estrogen receptor α from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in breast cancer

Figure 1

Validation of the PRDX1 antibody specificity using immunoblotting, RPPA and IHC platforms. (A) Immunoblotting shows a discrete signal, the intensity of which correlates with PRDX1 knockdown/overexpression across recombinant ZR-75-1 cell lines (V5-tagged PRDX1 protein runs at 25 kDa, with native protein at 22 kDa). (B) Correlation between Western blotting densitometry and RPPA log2 expression values from recombinant ZR-75-1 cell lines protein lysates. (C) Immunoblotting, (D) cell pellet arrays (upper panels: DAB and hematoxylin staining; lower panel: DAB staining only) and (E) automated analysis scoring from recombinant SKBR3 breast cancer cell lines (automated scoring includes data from cells stained with PRDX1 antibody or PBS-T only control). (F) Representation of tissue cores and associated mark-up images after automated analysis (x40 magnification). (G) Example of PRDX1 cytoplasmic staining. (ns: non-significant; **P <0.01; ***P <0.001). IHC, immunohistochemistry; PBS-T, phosphate-buffered saline with 0.1% Tween-20; PRDX1, peroxiredoxin 1; RPPA, reverse phase protein arrays.

Back to article page